We are independent & ad-supported. We may earn a commission for purchases made through our links.
Advertiser Disclosure
Our website is an independent, advertising-supported platform. We provide our content free of charge to our readers, and to keep it that way, we rely on revenue generated through advertisements and affiliate partnerships. This means that when you click on certain links on our site and make a purchase, we may earn a commission. Learn more.
How We Make Money
We sustain our operations through affiliate commissions and advertising. If you click on an affiliate link and make a purchase, we may receive a commission from the merchant at no additional cost to you. We also display advertisements on our website, which help generate revenue to support our work and keep our content free for readers. Our editorial team operates independently of our advertising and affiliate partnerships to ensure that our content remains unbiased and focused on providing you with the best information and recommendations based on thorough research and honest evaluations. To remain transparent, we’ve provided a list of our current affiliate partners here.
Technology

Our Promise to you

Founded in 2002, our company has been a trusted resource for readers seeking informative and engaging content. Our dedication to quality remains unwavering—and will never change. We follow a strict editorial policy, ensuring that our content is authored by highly qualified professionals and edited by subject matter experts. This guarantees that everything we publish is objective, accurate, and trustworthy.

Over the years, we've refined our approach to cover a wide range of topics, providing readers with reliable and practical advice to enhance their knowledge and skills. That's why millions of readers turn to us each year. Join us in celebrating the joy of learning, guided by standards you can trust.

What is Data Exclusivity?

Mary McMahon
By
Updated: May 17, 2024
Views: 6,738
Share

Data exclusivity is a form of protection available to manufacturers of prescription drugs, barring generic competitors from using the results of clinical trials performed by the drug developer in their own applications to regulatory agencies requesting permission to sell drugs. This protection lasts for a limited time, with the time frame depending on the nation. Companies with drugs in development argue that people should not be allowed to use their trial data without paying for it when they are applying for permission to sell competing generic formulations. Generic manufacturers believe data exclusivity keeps drug prices high, making it harder for low income people to access medications.

Clinical trials are expensive and can take a very long time. Companies invest a great deal of time and money in these trials for the purpose of determining if a medication is safe and finding out what conditions it can treat. Pharmaceutical companies may treat this data as proprietary, because it pertains to brand-name medications they make, and they want to recoup the process of drug discovery and research.

Companies can already obtain patents to protect the sales of their drug for a set period of time. Data exclusivity adds another layer of regulation. Companies with generic drugs may know their drugs are safe because of the original clinical trial results, but they cannot rely on those results when they apply to regulators to get permission to produce and sell their medications. They either need to run their own trials, or wait for the data exclusivity to expire so they can turn to the research from the original company.

This is a form of patent and trademark protection. For pharmaceutical companies, drug development is very costly, and many of the compounds drug companies invest in never make it to clinical trials, let alone the open market. If a competitor can immediately benefit from their research and sell a generic version at a lower price, the original company will have trouble finding buyers for the drug, and cannot hope to make up the expenses associated with producing it.

People concerned about the affordability of drugs in developing nations and low income communities argue that while patent protection and tools like data exclusivity are reasonable, they can hinder drug accessibility. Some people cannot afford to pay the list price for brand-name medications and may lose out on access to treatment, when a pharmaceutical company could produce a pharmacologically identical generic and offer it at a lower price. These patients must wait for drugs to go off patent, or hope that a drug company can negotiate a special license to produce generics for use in a specific region.

Share
WiseGeek is dedicated to providing accurate and trustworthy information. We carefully select reputable sources and employ a rigorous fact-checking process to maintain the highest standards. To learn more about our commitment to accuracy, read our editorial process.
Mary McMahon
By Mary McMahon

Ever since she began contributing to the site several years ago, Mary has embraced the exciting challenge of being a WiseGeek researcher and writer. Mary has a liberal arts degree from Goddard College and spends her free time reading, cooking, and exploring the great outdoors.

Editors' Picks

Discussion Comments
Mary McMahon
Mary McMahon

Ever since she began contributing to the site several years ago, Mary has embraced the exciting challenge of being a...

Learn more
Share
https://www.wisegeek.net/what-is-data-exclusivity.htm
Copy this link
WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.

WiseGeek, in your inbox

Our latest articles, guides, and more, delivered daily.